This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cambridge Major Laboratories Europe, B.V. Announces Successful FDA Inspection At Weert Facility

WEERT, The Netherlands, October 22, 2013 /PRNewswire/ --

Global pharmaceutical chemistry leader Cambridge Major Laboratories Europe, B.V. (CML-Europe) is pleased to announce the successful completion of its first Food and Drug Administration inspection. The inspection included a pre-approval inspection and general quality systems audit and concluded with no Form 483 being issued.

     (Logo: )

"This successful FDA inspection represents a major milestone for the CML-Europe facility," said Peter van Tilburg, President of CML-Europe. "We place Quality above all else, and I am so proud that the dedication and performance of the CML-Europe team resulted in this successful outcome."

The successful inspection is the culmination of efforts to demonstrate CML-Europe's ability to supply world-class development services and niche commercial APIs to its growing customer base.

"CML-Europe will always be committed to quality and strong leadership, and this commitment is evidenced by two significant recent hires," said Peter van Tilburg. In September 2013, CML-Europe hired Dr. Marcel Schreuder Goedheijt as Director Operations, and Mr. Jan Douwstra as Head of Production. Dr. Schreuder Goedheijt brings a wealth of chemical pharmaceutical and business experience from his previous positions at DSM, DSM Pharma Chemicals, MSD and Diosynth BV. Mr. Douwstra held previous positions at the Academic Medical Centre, Amsterdam and St. Radboud University Medical Centre, Nijmegen, as well as Abbott Healthcare B.V., Solvay Pharmaceuticals B.V. Weesp, and Smit & Zoon B.V. Amersfoort.

Cambridge Major Laboratories, Inc. announced its intent to merge with AAIPharma Services, Corp. on October 2, 2013.

About Cambridge Major Laboratories, Inc.

Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacturing. Operating from FDA-inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence, including: Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance. CML is a portfolio company of American Capital, Ltd. (NASDAQ: ACAS).

For more information on the company, visit  

About AAIPharma Services Corp.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs